

# ASX Announcement

## 22 May 2026

**Cogstate Limited**  
ABN 80 090 975 723

Level 32  
367 Collins Street  
Melbourne, Vic, 3000  
Australia

**P** +61 3 9664 1300  
**F** +61 3 9664 1301  
**W** [cogstate.com](http://cogstate.com)

## Joint Company Secretary Changes

Cogstate Limited (ASX: CGS) wishes to advise, in accordance with ASX Listing Rule 3.16.1, a change to its company secretarial arrangements effective today, 22 May 2026.

Ms Kristi Geddes has resigned as Joint Company Secretary to pursue other opportunities. The Board wishes to thank Ms Geddes for her contribution and service to the Company.

Concurrently, the Board is pleased to announce the appointment of the Company's Chief Financial Officer, Mr Darren Watson, as Joint Company Secretary, effective 22 May 2026.

Mr Watson has extensive financial leadership, deep knowledge of the Company's operations, and executive management experience making him well suited to the position. The Company's corporate governance and compliance functions will remain highly stable as Mr David Franks, appointed on 26 February 2021, will continue in his current role as Joint Company Secretary.

Following these changes, Mr Watson and Mr Franks will be jointly responsible for the company secretarial function. For the purposes of ASX Listing Rule 12.6, both Mr Watson and Mr Franks will be the persons responsible for communication with the ASX in relation to listing rule matters.

This announcement was authorised for release by the CEO of Cogstate Ltd. For further information contact: [companysecretary@cogstate.com](mailto:companysecretary@cogstate.com)

---

### About Cogstate

Cogstate Ltd (ASX: CGS) is a global Central Nervous System (CNS) endpoint innovations company that partners with drug developers to power complex neuroscience studies. Cogstate uniquely specializes in the science and service of CNS measurement to ensure clinical trial endpoint data is as accurate as it is actionable. Our applied technology solutions include fit-for-purpose data quality programs, advanced analytics, and digital cognitive testing to identify clear signals for confident decision-making. Building upon 25 years of customized collaborations, Cogstate is accelerating the next generation of CNS therapies. In the Healthcare market, Cogstate seeks to provide primary care physicians and consumers with brief, accurate and scientifically validated digital measures of cognition, with a focus on easy to use, self-administered tests that inform patients and save physician time. For more information, please visit [www.cogstate.com](http://www.cogstate.com).